Antibodies binding to citrullinated histone 2A and/or 4
Summary
USPTO granted Patent No. 12,590,143 B2 to Citryll B.V. for antibodies binding to citrullinated histone 2A and/or 4, covering therapeutic applications for Neutrophil Extracellular Trap (NET)-associated pathologies. The patent includes 13 claims and covers both the antibodies and binding fragments for use in treatment.
What changed
USPTO issued Patent No. 12,590,143 B2 to Citryll B.V. on March 31, 2026, covering antibodies and binding fragments directed against citrulline-containing epitopes derived from citrullinated histones 2A and/or 4. The patent claims priority to Application No. 17827488 (filed May 27, 2022) and includes 13 claims under CPC classifications C07K 16/18, A61P 19/02, and A61P 29/00.
Pharmaceutical companies developing treatments for NET-associated diseases—including rheumatoid arthritis, lupus, vasculitis, and sepsis—should conduct freedom-to-operate analyses before proceeding with related antibody therapeutics. Biotech firms and research institutions should review their pipelines for potential licensing opportunities or design-around strategies to avoid infringement on this newly granted patent.
What to do next
- Conduct freedom-to-operate analysis for any antibody development targeting NET-associated diseases
- Review existing pipelines for potential licensing needs with Citryll B.V.
- Update patent landscape assessments for citrullinated histone targeting therapies
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Antibodies binding to citrullinated histone 2A and/or 4
Grant US12590143B2 Kind: B2 Mar 31, 2026
Assignee
Citryll B.V.
Inventors
Jozef Maria Hendrik Raats, Renato Gerardus Silvano Chirivi, Johannes Wilhelmus Gerardus Van Rosmalen
Abstract
The invention provides antibodies or binding fragments thereof directed against citrulline-containing epitopes. The antibodies or binding fragments thereof of the invention can be used in therapy, for example in the treatment or prevention of Neutrophil Extracellular Trap (NET)-associated pathologies.
CPC Classifications
C07K 16/18 C07K 2317/24 C07K 2317/565 A61P 19/02 A61P 29/00 A61K 2039/505
Filing Date
2022-05-27
Application No.
17827488
Claims
13
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.